136 related articles for article (PubMed ID: 18922117)
21. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
[TBL] [Abstract][Full Text] [Related]
22. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
23. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
24. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
25. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
26. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
28. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin PM; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
N Engl J Med; 2018 Jul; 379(2):111-121. PubMed ID: 29860917
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
31. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
32. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
33. Impact of oncotype DX recurrence score in the management of breast cancer cases.
Nguyen MT; Stessin A; Nagar H; D'Alfonso TM; Chen Z; Cigler T; Hayes MK; Shin SJ
Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121
[TBL] [Abstract][Full Text] [Related]
34. Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
Turashvili G; Wen HY
Breast J; 2020 Jun; 26(6):1199-1207. PubMed ID: 32458521
[TBL] [Abstract][Full Text] [Related]
35. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
[TBL] [Abstract][Full Text] [Related]
36. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Andre F; Ismaila N; Henry NL; Somerfield MR; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Van Poznak C; Wolff AC; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1956-1964. PubMed ID: 31150316
[TBL] [Abstract][Full Text] [Related]
37. The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Ethier JL; Amir E
Mol Diagn Ther; 2016 Aug; 20(4):307-13. PubMed ID: 27235162
[TBL] [Abstract][Full Text] [Related]
38. [Genomic signature in breast cancer: Oncotype DX(®)].
Teig B
Ann Pathol; 2013 Jun; 33(3):225-8. PubMed ID: 23790668
[No Abstract] [Full Text] [Related]
39. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
Hwang ES; Esserman L
Ann Surg Oncol; 2004 Jan; 11(1 Suppl):37S-43S. PubMed ID: 15015708
[TBL] [Abstract][Full Text] [Related]
40. Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
Sparano JA; Crager MR; Tang G; Gray RJ; Stemmer SM; Shak S
J Clin Oncol; 2021 Feb; 39(6):557-564. PubMed ID: 33306425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
